Machiels Alec

CIK 00014966873 companiesWALTHAM, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001496687

Recent Transactions

50 trades

Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-01+7,961→ 384,989 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2026-01-01+14,684→ 14,684 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-01+6,267→ 377,028 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2025-01-01+11,199→ 11,199 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-01+3,341→ 370,761 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-01-01$59.86/sh+5,748→ 5,748 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-11-17$2.67/sh+1,250→ 368,670 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-11-17$47.74/sh−1,250→ 367,420 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-11-17−1,250→ 0 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-10-17−1,250→ 1,250 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-10-17$2.67/sh+1,250→ 368,670 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-10-17$48.50/sh−1,250→ 367,420 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-09-18−1,250→ 2,500 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-18$45.00/sh−1,250→ 367,420 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-18$2.67/sh+1,250→ 368,670 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-15$45.34/sh−1,250→ 367,420 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-15$2.67/sh+1,250→ 368,670 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-09-15−1,250→ 3,750 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-07-21$2.67/sh+49,779→ 367,420 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-07-21−49,779→ 5,000 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-07-20−50,000→ 54,779 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-07-20$2.67/sh+50,000→ 317,641 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-07-17$64.79/sh−1,250→ 267,641 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-07-17$2.67/sh+1,250→ 268,891 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-07-17−1,250→ 104,779 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-06-20$2.67/sh+1,250→ 268,891 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-06-20−1,250→ 106,029 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-06-20$88.41/sh−1,250→ 267,641 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-05-17−1,250→ 107,279 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-05-17$2.67/sh+1,250→ 268,891 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-05-17$88.66/sh−1,250→ 267,641 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-04-17−1,250→ 108,529 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-04-17$81.05/sh−1,250→ 267,641 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-04-17$2.67/sh+1,250→ 268,891 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-03-17$64.03/sh−1,250→ 267,641 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-03-17$2.67/sh+1,250→ 268,891 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-03-17−1,250→ 109,779 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-17$52.38/sh−1,250→ 267,641 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-17$2.67/sh+1,250→ 268,891 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-02-17−1,250→ 111,029 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-17$2.67/sh+1,250→ 268,891 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-01-17−1,250→ 112,279 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-17$52.42/sh−1,250→ 267,641 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-01+3,867→ 267,641 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-01-01+7,441→ 7,441 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-12-15$52.35/sh−1,250→ 263,774 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-12-15−1,250→ 113,529 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-12-15$2.67/sh+1,250→ 265,024 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-11-15$48.01/sh−1,250→ 263,774 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-11-15$2.67/sh+1,250→ 265,024 total

Companies

Recent Filings

Address

C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR

WALTHAM, MA, 02451

View on SEC.gov